​

Standard BioTools (LAB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LAB Stock Forecast

Standard BioTools (LAB) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $3.25, with a high of $3.25 and a low of $3.25. This represents a 119.59% increase from the last price of $1.48.

High: $3.25 Avg: $3.25 Low: $3.25 Last Closed Price: $1.48

LAB Stock Rating

Standard BioTools stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (60.00%), 4 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 4 6 Strong Sell Sell Hold Buy Strong Buy

LAB Price Target Upside V Benchmarks

TypeNameUpside
StockStandard BioTools119.59%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks19.58%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.48$1.48$1.48
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-12--3
Nov, 25-12--3
Oct, 25-12--3
Sep, 25-12--3
Aug, 25-21--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 04, 2024Matthew StantonJefferies$3.25$2.6622.18%119.59%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 13, 2025Cowen & Co.BuyHolddowngrade
Feb 27, 2025KeyBancOverweightSector Weightdowngrade
Sep 16, 2024Cowen & Co.BuyBuyhold
Apr 16, 2024Cowen & Co.Buyinitialise
Apr 04, 2024JefferiesBuyinitialise
Jul 12, 2023KeyBancOverweightinitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-0.74$-0.78$-2.43$-0.94$-0.52---
Avg Forecast$-0.55$-0.94$-1.00$-0.94$-0.36$-0.20$-0.08$-0.04
High Forecast$-0.54$-0.91$-0.99$-0.91$-0.35$-0.19$-0.07$-0.04
Low Forecast$-0.57$-0.96$-1.02$-0.97$-0.37$-0.21$-0.08$-0.04
Surprise %34.55%-17.02%143.00%-44.44%---

Revenue Forecast

$50M $100M $150M $200M $250M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$138.14M$130.58M$97.95M$106.34M$174.43M---
Avg Forecast$144.27M$125.00M$124.40M$103.00M$171.20M$186.93M$224.21M$252.70M
High Forecast$146.95M$127.33M$126.43M$104.67M$175.91M$189.08M$232.11M$259.65M
Low Forecast$141.27M$122.40M$123.23M$101.33M$167.39M$184.79M$216.32M$247.07M
Surprise %-4.24%4.46%-21.26%3.24%1.89%---

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-53.02M$-59.24M$-190.10M$-74.66M$-184.90M---
Avg Forecast$-43.83M$-74.41M$-79.16M$-74.66M$-28.33M$-15.89M$-6.08M$-3.18M
High Forecast$-42.64M$-72.40M$-78.19M$-72.26M$-27.42M$-15.37M$-5.88M$-3.07M
Low Forecast$-44.89M$-76.21M$-80.84M$-77.07M$-29.24M$-16.40M$-6.27M$-3.28M
Surprise %20.98%-20.39%140.14%-552.66%---

LAB Forecast FAQ

Is Standard BioTools stock a buy?

Standard BioTools stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Standard BioTools is a favorable investment for most analysts.

What is Standard BioTools's price target?

Standard BioTools's price target, set by 10 Wall Street analysts, averages $3.25 over the next 12 months. The price target range spans from $3.25 at the low end to $3.25 at the high end, suggesting a potential 119.59% change from the previous closing price of $1.48.

How does Standard BioTools stock forecast compare to its benchmarks?

Standard BioTools's stock forecast shows a 119.59% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (19.58%).

What is the breakdown of analyst ratings for Standard BioTools over the past three months?

  • December 2025: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is Standard BioTools’s EPS forecast?

Standard BioTools's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.2, marking a -61.54% decrease from the reported $-0.52 in 2024. Estimates for the following years are $-0.08 in 2026, and $-0.04 in 2027.

What is Standard BioTools’s revenue forecast?

Standard BioTools's average annual revenue forecast for its fiscal year ending in December 2025 is $186.93M, reflecting a 7.17% increase from the reported $174.43M in 2024. The forecast for 2026 is $224.21M, and $252.7M for 2027.

What is Standard BioTools’s net income forecast?

Standard BioTools's net income forecast for the fiscal year ending in December 2025 stands at $-15.886M, representing a -91.41% decrease from the reported $-185M in 2024. Projections indicate $-6.076M in 2026, and $-3.177M in 2027.